Premium
Structure‐Guided Discovery of a Potent and Selective Cell‐Active Inhibitor of SETDB1 Tudor Domain
Author(s) -
Guo Yinping,
Mao Xin,
Xiong Liang,
Xia Anjie,
You Jing,
Lin Guifeng,
Wu Chengyong,
Huang Luyi,
Wang Yiwei,
Yang Shengyong
Publication year - 2021
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.202017200
Subject(s) - methyltransferase , histone , histone methyltransferase , histone h3 , enzyme , acetylation , biology , cell culture , gene silencing , chemistry , biochemistry , microbiology and biotechnology , gene , computational biology , methylation , genetics
SET domain bifurcated protein 1 (SETDB1) is a histone lysine methyltransferase that promotes the silencing of some tumour suppressor genes and is overexpressed in many cancers. SETDB1 contains a unique tandem tudor domain (TTD) that recognizes histone H3 sequences containing both methylated and acetylated lysines. Beginning with the identification of a hit compound ( Cpd1 ), we discovered the first potent and selective small molecule SETDB1‐TTD inhibitor ( R , R )‐59 through stepwise structure‐guided optimization. ( R , R )‐59 showed a K D value of 0.088±0.045 μM in the ITC assay. The high potency of ( R , R )‐59 was well explained by the cocrystal structure of the ( R , R )‐59 ‐TTD complex. ( R , R )‐59 is an endogenous binder competitive inhibitor. Evidence has also demonstrated its cellular target engagement. Interestingly, the enantiomer ( S , S )‐59 did not show activity in all the assays, highlighting the potential of ( R , R )‐59 as a tool compound in exploring the biological functions of SETDB1‐TTD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom